AIMS: Eribulin mesilate is an inhibitor of microtubule dynamics that is approved for the treatment of late-stage metastatic breast cancer. Neutropenia is one of the major dose-limiting adverse effects of eribulin. The objective of this analysis was to develop a population pharmacokinetic-pharmacodynamic model for eribulin-associated neutropenia. METHODS: A combined data set of 12 phase I, II and III studies for eribulin mesilate was analysed. The population pharmacokinetics of eribulin was described using a previously developed model. The relationship between eribulin pharmacokinetic and neutropenia was described using a semi-physiological lifespan model for haematological toxicity. Patient characteristics predictive of increased sensitivity to develop neutropenia were evaluated using a simulation framework. RESULTS: Absolute neutrophil counts were available from 1579 patients. In the final covariate model, the baseline neutrophil count (ANC0) was estimated to be 4.03 × 10(9) neutrophils l(-1) [relative standard error (RSE) 1.2%], with interindividual variability (IIV, 37.3 coefficient of variation % [CV%]). The mean transition time was estimated to be 109 h (RSE 1.8%, IIV 13.9CV%), the feedback constant (γ) was estimated to be 0.216 (RSE 1.4%, IIV 12.2CV%), and the linear drug effect coefficient (SLOPE) was estimated to be 0.0451 μg l(-1) (RSE 3.2%, IIV 54CV%). Albumin, aspartate transaminase and receival of granulocyte colony-stimulating factor (G-CSF) were identified as significant covariates on SLOPE, and albumin, bilirubin, G-CSF, alkaline phosphatase and lactate dehydrogenase were identified as significant covariates on mean transition time. CONCLUSIONS: The developed model can be applied to investigate optimal treatment strategies quantitatively across different patient groups with respect to neutropenia. Albumin was identified as the most clinically important covariate predictive of interindividual variability in the neutropenia time course.
AIMS: Eribulin mesilate is an inhibitor of microtubule dynamics that is approved for the treatment of late-stage metastatic breast cancer. Neutropenia is one of the major dose-limiting adverse effects of eribulin. The objective of this analysis was to develop a population pharmacokinetic-pharmacodynamic model for eribulin-associated neutropenia. METHODS: A combined data set of 12 phase I, II and III studies for eribulin mesilate was analysed. The population pharmacokinetics of eribulin was described using a previously developed model. The relationship between eribulin pharmacokinetic and neutropenia was described using a semi-physiological lifespan model for haematological toxicity. Patient characteristics predictive of increased sensitivity to develop neutropenia were evaluated using a simulation framework. RESULTS: Absolute neutrophil counts were available from 1579 patients. In the final covariate model, the baseline neutrophil count (ANC0) was estimated to be 4.03 × 10(9) neutrophils l(-1) [relative standard error (RSE) 1.2%], with interindividual variability (IIV, 37.3 coefficient of variation % [CV%]). The mean transition time was estimated to be 109 h (RSE 1.8%, IIV 13.9CV%), the feedback constant (γ) was estimated to be 0.216 (RSE 1.4%, IIV 12.2CV%), and the linear drug effect coefficient (SLOPE) was estimated to be 0.0451 μg l(-1) (RSE 3.2%, IIV 54CV%). Albumin, aspartate transaminase and receival of granulocyte colony-stimulating factor (G-CSF) were identified as significant covariates on SLOPE, and albumin, bilirubin, G-CSF, alkaline phosphatase and lactate dehydrogenase were identified as significant covariates on mean transition time. CONCLUSIONS: The developed model can be applied to investigate optimal treatment strategies quantitatively across different patient groups with respect to neutropenia. Albumin was identified as the most clinically important covariate predictive of interindividual variability in the neutropenia time course.
Authors: J G C van Hasselt; A H Boekhout; J H Beijnen; J H M Schellens; A D R Huitema Journal: Clin Pharmacol Ther Date: 2011-06-01 Impact factor: 6.875
Authors: Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Comput Methods Programs Biomed Date: 2010-06-02 Impact factor: 5.428
Authors: A S Zandvliet; W S Siegel-Lakhai; J H Beijnen; W Copalu; M-C Etienne-Grimaldi; G Milano; J H M Schellens; A D R Huitema Journal: Clin Pharmacol Ther Date: 2007-09-12 Impact factor: 6.875
Authors: Javier Cortes; Linda Vahdat; Joanne L Blum; Chris Twelves; Mario Campone; Henri Roché; Thomas Bachelot; Ahmad Awada; Robert Paridaens; Anthony Goncalves; Dale E Shuster; Jantien Wanders; Fang Fang; Renuka Gurnani; Elaine Richmond; Patricia E Cole; Simon Ashworth; Mary Ann Allison Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544
Authors: Elena Soto; Ron J Keizer; Iñaki F Trocóniz; Alwin D R Huitema; Jos H Beijnen; Jan H M Schellens; Jantien Wanders; Josep María Cendrós; Rosendo Obach; Concepción Peraire; Lena E Friberg; Mats O Karlsson Journal: Invest New Drugs Date: 2010-05-07 Impact factor: 3.850
Authors: Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves Journal: Lancet Date: 2011-03-02 Impact factor: 79.321
Authors: Linda T Vahdat; Brian Pruitt; Carol J Fabian; Ragene R Rivera; David A Smith; Elizabeth Tan-Chiu; Jonathan Wright; Antoinette R Tan; Noshir A Dacosta; Ellen Chuang; John Smith; Joyce O'Shaughnessy; Dale E Shuster; Nicole L Meneses; Kumari Chandrawansa; Fang Fang; Patricia E Cole; Simon Ashworth; Joanne L Blum Journal: J Clin Oncol Date: 2009-04-06 Impact factor: 44.544
Authors: Sanjay Goel; Alain C Mita; Monica Mita; Eric K Rowinsky; Quincy S Chu; Nancy Wong; Christopher Desjardins; Fang Fang; Mendel Jansen; Dale E Shuster; Sridhar Mani; Chris H Takimoto Journal: Clin Cancer Res Date: 2009-06-09 Impact factor: 12.531
Authors: Anthe S Zandvliet; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema Journal: J Pharmacokinet Pharmacodyn Date: 2009-02-07 Impact factor: 2.745
Authors: Huixin Yu; Neeltje Steeghs; Jacqueline S L Kloth; Djoeke de Wit; J G Coen van Hasselt; Nielka P van Erp; Jos H Beijnen; Jan H M Schellens; Ron H J Mathijssen; Alwin D R Huitema Journal: Br J Clin Pharmacol Date: 2015-05 Impact factor: 4.335
Authors: J G Coen van Hasselt; Matthew L Rizk; Mallika Lala; Cynthia Chavez-Eng; Sandra A G Visser; Thomas Kerbusch; Meindert Danhof; Gauri Rao; Piet H van der Graaf Journal: Br J Clin Pharmacol Date: 2016-04-01 Impact factor: 4.335
Authors: Huixin Yu; Julie M Janssen; Vincent A de Weger; Bastiaan Nuijen; Rik E Stuurman; Serena Marchetti; Jan H M Schellens; Jos H Beijnen; Thomas P C Dorlo; Alwin D R Huitema Journal: Invest New Drugs Date: 2020-04-19 Impact factor: 3.850
Authors: N M Smith; J R Lenhard; K R Boissonneault; C B Landersdorfer; J B Bulitta; P N Holden; A Forrest; R L Nation; J Li; B T Tsuji Journal: Clin Microbiol Infect Date: 2020-02-12 Impact factor: 8.067
Authors: Gerardus W J Frederix; Johan G C van Hasselt; Jan H M Schellens; Anke M Hövels; Jan A M Raaijmakers; Alwin D R Huitema; Johan L Severens Journal: Pharmacoeconomics Date: 2014-01 Impact factor: 4.981
Authors: J G C van Hasselt; A Gupta; Z Hussein; J H Beijnen; J H M Schellens; A D R Huitema Journal: CPT Pharmacometrics Syst Pharmacol Date: 2015-06-30
Authors: J G C van Hasselt; A Gupta; Z Hussein; J H Beijnen; J H M Schellens; A D R Huitema Journal: CPT Pharmacometrics Syst Pharmacol Date: 2015-06-30